#China #Shanghai #Sanyou Bio #Antibody Discovery #AI-STAL 2.0

Introduction

In the rapidly evolving field of drug research and development (R&D), especially in the realm of antibodies, peptides, and unique binding proteins, the speed and efficiency of early-stage molecule discovery play a pivotal role in the success or failure of projects. Traditional molecular discovery approaches often struggle to balance the timeline with quality. Conventional screening methods can extend over months, hindering responses to fast-changing market dynamics. Compounding these issues, the disconnect between the throughput of wet-lab screening and digital evaluation systems often leaves valuable drug candidate molecules buried beneath vast amounts of data. Inadequate predictions of expression levels in eukaryotic systems further exacerbate the challenges, resulting in delayed assessments and diminished R&D success rates.

To tackle these challenges, Sanyou Bio introduces its innovative "14-Day Lead Molecule Discovery Workflow." This cutting-edge approach, designed for various molecule types including antibodies, peptides, and binding proteins, leverages artificial intelligence (AI) and an intelligent core platform to condense the entire process from library panning to core molecule validation into an astonishing 14 days. This revolutionary solution disrupts the conventional linear sequencing of biological experiments, employing a deep closed-loop combination of both in silico and in vitro methodologies. The result is the identification of high-quality candidate molecules in an exceptionally brief timeframe while also diminishing developability risks at the early stages—ultimately providing biopharmaceutical partners worldwide with a greatly accelerated pathway from sequence to validated product.

Platform Overview

The remarkable capabilities of AI-STAL 2.0 arise from its extensive and sophisticated molecular repository, which is not simply a collection from a single source but a comprehensive, three-dimensional ecosystem encompassing multiple ultra-trillion-scale, highly specialized sub-libraries. These include libraries specifically designed for fully human antibodies, novel targeted proteins, cyclic peptides, as well as immune antibody libraries from various species like alpacas and rabbits. The impressive synergy among these libraries empowers AI-STAL 2.0 to pinpoint high-potential lead molecules from an immense diversity spectrum within just 14 days, laying a robust foundation for groundbreaking biological discoveries.

Since its inception, the AI-STAL 2.0 platform has successfully completed over 1,300 molecule discovery projects, supported the advancement of hundreds of PCC projects, and has seen more than ten of these enter the crucial clinical stage.

Advantages of AI-STAL 2.0

AI-STAL 2.0 streamlines the innovation and validation timeline to a mere 14 days through a series of intelligent workstations that facilitate rapid discovery. The process starts with AI-guided activity screening and digital panning. It then transitions through intelligent sequence-to-structure mapping, solubility prediction, and culminates in eukaryotic expression validation and functional assessments on Day 14. This innovative methodology achieves a full-chain closed-loop from the generation of molecules through to their validation, significantly enhancing both the quality and developability of the candidate molecules.

1. AI-Guided Activity Screening for Accelerated Primary Screening

Traditional panning methods, which heavily rely on physical selections, may be biased and limited in library scope. AI-STAL 2.0 revolutionizes this by implementing AI-driven activity screening that utilizes advanced algorithms to perform virtual screening across super-trillion antibody libraries. This enables the rapid identification of promising core molecules while simultaneously integrating solubility predictions and real-time affinity validation. Dangerous candidates that may lead to aggregation or those hard to express are eliminated early in the screening process, thus enhancing the overall success rate and paving the way for a quality-driven discovery phase.

2. AI Sequence-Structure Analysis for Molecular Configurations

AI-STAL 2.0 showcases impressive capabilities in structural biology. Through advanced sequence-to-structure mapping technology, it can convert selected amino acid sequences into detailed three-dimensional models quickly. For types of molecules like peptides and single-domain antibodies, whose functions hinge on correct spatial configurations, this step delivers essential insights that guide further optimizations, ensuring resources aren't wasted on ineffective candidates.

3. AI-Optimized Production and Eukaryotic Expression Validation

This innovative workflow seamlessly integrates computational design with experimental validation. The system uses AI to devise optimal production strategies for candidate molecules, followed by validation in eukaryotic systems that closely mimic the complex post-translational modifications essential for the activity of intricate molecule types. Such quality assurance ensures that the final molecules not only model well computationally but also exhibit excellent biological activity.

4. Comprehensive Delivery of Candidate Molecules

AI-STAL 2.0 boasts a complete closed-loop system from molecular design right through to validation in merely 14 days. By the end of Day 14, research teams receive thoroughly vetted candidate molecules that have undergone real affinity verification, structural mapping, and eukaryotic expression optimization. This facilitates an unprecedented acceleration in the innovative drug pipeline process.

Case Studies and Results

Most antibody candidates derived from the AI-STAL 2.0 screening demonstrate excellent protein-level binding activity as evidenced by ELISA affinity measurements. Additionally, cell-level assessments using FACS analysis reveal that these antibody candidates bind effectively to designated antigen-expressing cell lines.

Conclusion

Sanyou Bio's groundbreaking 14-Day Candidate Antibody Discovery Workflow epitomizes the integration of intelligent R&D processes, signaling an evolution towards rapidity, throughput, and enhanced certainty for drug development. With each key phase reflecting a data-centric, closed-loop system, this workflow showcases the versatility necessary for a wide variety of molecular types. Designed to maintain the activity of released molecules, it establishes a solid molecular foundation for subsequent stages of preclinical development. Looking ahead, Sanyou Bio is poised to continue exploring the integration of AI and biotechnology, striving for the automation of R&D processes by 2026 and embracing future advancements that can expedite the path to clinic-ready innovative medications for patients around the globe.